My research investigates AU403, a novel LXR agonist, as a potential treatment for frontotemporal dementia. Using mouse brain slice models, the study shows that AU403 restores damaged myelin, improves neuronal communication, and reverses disease-like symptoms, offering hope for a condition with no approved therapies.

This research focuses on developing reliable blood-based biomarkers to evaluate new treatments for hereditary frontotemporal dementia. By identifying an imbalance between two key molecules, progranulin and prosaposin, the work aims to provide accurate measures of treatment effectiveness and bring hope to families carrying this devastating genetic condition